dimethyl 4-fluorobenzylphosphonate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: dimethyl 4-fluorobenzylphosphonate
• 英文别名: (4-fluoro-benzyl)-phosphonic acid dimethyl ester；Dimethyl (4-fluorobenzyl)phosphonate；1-(dimethoxyphosphorylmethyl)-4-fluorobenzene
• 化学式: C₉H₁₂FO₃P
• mdl: MFCD18064630
• 分子量: 218.165
• InChiKey: PXRXOCSAKCSLKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  dimethyl 4-fluorobenzylphosphonate 在 三氯氧磷 作用下， 反应 1.5h， 生成 C₈H₉ClFO₂P
  参考文献：
  名称：

  Tetrahydroquinolinyl phosphinamidates and phosphonamidates enhancing tolerance towards drought stress in crops via interaction with ABA receptor proteins

  摘要：

  New phosphorous-containing lead structures against drought stress in crops interacting with RCAR/(PYR/PYL) receptor proteins were identified starting from in-depth SAR studies of related sulfonamide lead structures and protein docking studies. A converging 6-step synthesis via phosphinic chlorides and phosphono chloridates as key intermediates afforded envisaged tetrahydroquinolinyl phosphinamidates and phosphonamidates. Whilst tetrahydroquinolinyl phosphonamidates 13a,b exhibited low to moderate target affinities, the corresponding tetrahydroquinolinyl phosphinamidates 12a,b revealed confirmed strong affinities for RCAR/ (PYR/PYL) receptor proteins in Arabidopsis thaliana on the same level as essential plant hormone abscisic acid (ABA) combined with promising efficacy against drought stress in vivo (broad-acre crops wheat and canola).

  DOI：

  10.1016/j.bmc.2020.115725
• 作为产物：
  描述：

  对氟苯甲醇 在 bis(η3-allyl-μ-chloropalladium(II)) 、 三乙胺 、 双(2-二苯基磷苯基)醚 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 dimethyl 4-fluorobenzylphosphonate
  参考文献：
  名称：

  用磷亲核试剂对碳酸苄酯进行钯催化的苄基取代

  摘要：

  在钯催化剂 [Pd(η3-烯丙基)Cl]2-DPEphos 存在下，各种碳酸苄酯与膦酸二甲酯或氧化二苯基膦反应，以高产率得到苄基膦酸二甲酯和苄基二苯基氧化膦。催化膦酰化应用于从苄酯合成烯烃的一锅法。

  DOI：

  10.1246/cl.170901

文献信息

• Continuous flow photocyclization of stilbenes – scalable synthesis of functionalized phenanthrenes and helicenes
  作者：Quentin Lefebvre、Marc Jentsch、Magnus Rueping

  DOI：10.3762/bjoc.9.221

  日期：——

  A continuous flow oxidative photocyclization of stilbene derivatives has been developed which allows the scalable synthesis of backbone functionalized phenanthrenes and helicenes of various sizes in good yields.

  已经开发了二苯乙烯衍生物的连续流动氧化光环化，它允许以良好的产率大规模合成各种尺寸的骨架官能化菲和螺旋。
• Arylmethylphosphonates and phosphonic acids useful as anti-inflammatory
  申请人：The Upjohn Company

  公开号：US05593980A1

  公开（公告）日：1997-01-14

  This invention provides a new use of acids, esters, and salts of arylmethylphosphonates of Formula I, ##STR1## or a phosphonic acid of Formula II ##STR2## and derivatives as anti-inflammatory and anti-arthritic agents. Representative compounds include 4-dodecyloxybenzylphosphonic acid dimethyl ester, (2-naphthalenylmethyl)phosphonic acid dimethyl ester, and ([1,1'-biphenyl]-2-ylmethyl)phosphonic acid dimethyl ester.

  这项发明提供了一种新的使用方法，将公式I的芳基甲基膦酸酯和盐，或公式II的膦酸和衍生物用作抗炎和抗关节炎药物。代表性化合物包括4-十二烷氧基苯甲基膦酸二甲酯，(2-萘基甲基)膦酸二甲酯和([1,1'-联苯]-2-基)膦酸二甲酯。
• INHIBITORS OF TYROSINE KINASES AND USES THEREOF
  申请人：Jankowski D. Orion

  公开号：US20080039426A1

  公开（公告）日：2008-02-14

  Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided.

  本文披露了一些抑制特定酪氨酸激酶活性的化合物。本文还披露了制备这些化合物的方法。此外，还披露了包括这些化合物的药物组合物。提供了使用这些化合物，单独或与其他治疗剂联合使用，用于治疗酪氨酸激酶介导的疾病或状况或酪氨酸激酶依赖性疾病或状况的方法。
• Inhibitors of tyrosine kinases and uses thereof
  申请人：Pharmacyclics, Inc.

  公开号：US08067395B2

  公开（公告）日：2011-11-29

  Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided.

  本文披露了一些抑制特定酪氨酸激酶活性的化合物。公开了制备这些化合物的方法。还披露了包括这些化合物的药物组合物。提供了使用这些化合物单独或与其他治疗剂联合治疗酪氨酸激酶介导的疾病或状况或酪氨酸激酶依赖性疾病或状况的方法。
• WO2007/87068
  申请人：——

  公开号：——

  公开（公告）日：——